GMAB vs JAZZ
Genmab A/S and Jazz Pharmaceuticals plc, both Healthcare
Genmab A/S is the larger company at $16B against $14B. Over the past year JAZZ returned +123% against +49% for GMAB. Ryufin's sector-relative Smart Score puts GMAB ahead, 9/10 against 6/10.
| Figure | GMAB | JAZZ |
|---|---|---|
| Last close | $33.75 | $249 |
| Market cap | $16B | $14B |
| 1-year return | +49% | +123% |
| 5-year return | -25% | +46% |
| Ryufin Smart Scoresector-relative, 1–10 | 9/10 | 6/10 |
Figures from SEC filings and end-of-day closes. Highlighting marks the higher or lower number, which is not the same as the better investment, a low P/E can be a warning and a high one can be deserved.
Genmab A/S
Revenue of $12B in H2 2024, net income $5.1B.
Jazz Pharmaceuticals plc
Revenue of $1.1B in Q1 2026, net income $293M. Its largest reported line is Oncology, 31% of the disclosed total.
Open these two in the interactive comparison to add more names, change the period or read the correlation.